Kathrin Brockmann
Overview
Explore the profile of Kathrin Brockmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
3028
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan M, Iwaki H, Bandres-Ciga S, Sosero Y, Shoai M, Brockmann K, et al.
medRxiv
. 2025 Feb;
PMID: 39974079
Polygenic risk scores (PRS) in Parkinson's disease (PD) are associated with disease risk. Recently, pathway-specific PRS have been created to take advantage of annotations inking variants to biological pathways or...
2.
Encarna Mico-Amigo M, Kingma I, Heinzel S, Solbrig S, Hobert M, Elshehabi M, et al.
J Parkinsons Dis
. 2025 Feb;
:1877718X241306141.
PMID: 39973512
Background: Development of objective, reliable and easy-to-use methods to detect the onset of motor changes in Parkinson's disease (PD) is required to identify the temporal window in which neuromodulatory therapies...
3.
Porsche S, Klietz M, Greten S, Piot I, Jensen I, Wegner F, et al.
Mov Disord Clin Pract
. 2025 Jan;
PMID: 39868903
Background: Patients with Progressive Supranuclear Palsy (PSP) suffer from several neuropsychological impairments. These mainly affect the frontal lobe and subcortical brain structures. However, a scale for the assessment of cognitive...
4.
Kastner L, Suenkel U, von Thaler A, Eschweiler G, Dankowski T, Mychajliw C, et al.
Front Public Health
. 2024 Dec;
12:1456829.
PMID: 39737450
Introduction: Social isolation is a main risk factor for loneliness, health issues and psychological diseases. With its restriction measures, the coronavirus pandemic has led to an objective reduction in meaningful...
5.
Maass F, Canaslan S, van Riesen C, Hermann P, Schmitz M, Schulte C, et al.
J Neurol
. 2024 Dec;
272(1):52.
PMID: 39666067
Background: It is well known that myelin disruption and neuroinflammation are early and distinct pathological hallmarks in multiple system atrophy (MSA) as well as in idiopathic Parkinson's disease and in...
6.
Ma Y, Farris C, Weber S, Schade S, Nguyen H, Perez-Soriano A, et al.
Lancet Neurol
. 2024 Nov;
23(12):1225-1237.
PMID: 39577923
Background: The pathological hallmarks of multiple system atrophy and Parkinson's disease are, respectively, misfolded-α-synuclein-laden glial cytoplasmic inclusions and Lewy bodies. CSF-soluble misfolded α-synuclein aggregates (seeds) are readily detected in people...
7.
Schalkamp A, Lerche S, Wurster I, Roeben B, Zimmermann M, Fries F, et al.
Front Aging Neurosci
. 2024 Oct;
16:1447944.
PMID: 39474283
Introduction: With age, sensory, cognitive, and motor abilities decline, and the risk for neurodegenerative disorders increases. These impairments influence the quality of life and increase the need for care, thus...
8.
Lerche S, Wurster I, Valente E, Avenali M, Samaniego D, Martinez-Vicente M, et al.
NPJ Parkinsons Dis
. 2024 Oct;
10(1):198.
PMID: 39448669
Variants in GBA1 result in dysregulated sphingolipids. We investigated five CSF d18:1 sphingolipid species in a longitudinal multicenter cohort comprising people with Parkinson's Disease and Dementia with Lewy bodies with...
9.
Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, et al.
Nat Med
. 2024 Oct;
30(12):3669-3675.
PMID: 39379705
The Phase II trial of Anti-alpha-Synuclein Antibody in Early Parkinson's Disease (PASADENA) is an ongoing double-blind, placebo-controlled trial evaluating the safety and efficacy of prasinezumab in early-stage Parkinson's disease (PD)....
10.
Katzdobler S, Nubling G, Klietz M, Fietzek U, Palleis C, Bernhardt A, et al.
J Neurol
. 2024 Sep;
271(10):6991-6999.
PMID: 39254698
Background: Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive...